解读IRC评价标准--课件

解读IRC评价标准在实体瘤中的应用LOGOBreakthrough of the year 2013 WhyWhy？lAntibodiesagainstCTLA-4lAntibodiesagainstPD-1lChimericantigenreceptortherapy,orCARtherapyCAR therapyCAR therapyAdoptive cell transfer therapy with CAR-engineered T cellsResultResultImmunity and Cancer:immunoediting PD-L1 in CanceruExpressed on cell surface of 30%solid tumors and selected hematologic malignancies;uInhibits anti-tumor immune responses.PD-1 pathway immunotherapyu2050%response rate in clinical trialsuPD-1 pathway antagonists show broad anti-tumor activity response in:melanoma,RCC,NSCLC,gastric,head and neck,ovarian,colon malignancies.Patterns of response to ipilimumab observed in advanced melanomaClin Cancer Res 2009;15:7412-7420.PD?Resected metastatic melanoma tumor nodule of the lungSD may also be viewed as an indicator of meaningful therapeutic effectlLATEBREAKINGABSTRACT:Pooledanalysisoflong-termsurvivaldatafromphaseIIandphaseIIItrialsofipilimumabinmetastaticorlocallyadvanced,unresectablemelanomaln4846pts,medianOSwas9.5months(95%CI:9.010.0)withaplateauintheOScurvebeginningaroundyear3for21%ofpts.lORRrangefrom10-15%Immune-Related Response CriterialTumorBurden=SPDindex lesions+SPDnew,measurablelesionsShifted from PD by the WHOcriteria to response per irRCAssociation of OS with response using WHO criteria or irRCPatterns of Response in Patients with Pretreated Metastatic MelanomaCancer Investigation,30:712720,2012Early Response to TherapyEarly Response to TherapyGradual/Delayed ResponseGradual/Delayed ResponseResponse After Progressive DiseaseResponse After Progressive DiseaseInitial New Lesions with Superior Initial New Lesions with Superior Response on RetreatmentResponse on RetreatmentMixed Response with Response on Mixed Response with Response on RetreatmentRetreatmentResponse evaluation criteria in solid tumourWe need new criteria?Change in Target Lesions From Baseline After Nivolumab TherapyNSCLCanti-PD-1;BMS-936558Combination of both Combination of both 2014.07